NCT06609928 - FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 24, 2025

Primary Completion Date

October 1, 2027

Study Completion Date

October 1, 2042

Conditions

Recurrent Childhood Acute Myeloid LeukemiaRefractory Childhood Acute Myeloid Leukemia

Interventions

BIOLOGICAL

FOLR1 CAR T-cells

Given IV

PROCEDURE

Biospecimen Collection

Undergo CSF and blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

DRUG

Cyclophosphamide

Given IV

PROCEDURE

Echocardiography

Undergo ECHO

DRUG

Fludarabine

Given IV

PROCEDURE

Pheresis

Undergo apheresis

PROCEDURE

Positron Emission Tomography

Undergo PET

Trial Locations (1)

RECRUITING

Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle